skip to main content

Title: Delivery-mediated exosomal therapeutics in ischemia–reperfusion injury: advances, mechanisms, and future directions

Ischemia-reperfusion injury (IRI) poses significant challenges across various organ systems, including the heart, brain, and kidneys. Exosomes have shown great potentials and applications in mitigating IRI-induced cell and tissue damage through modulating inflammatory responses, enhancing angiogenesis, and promoting tissue repair. Despite these advances, a more systematic understanding of exosomes from different sources and their biotransport is critical for optimizing therapeutic efficacy and accelerating the clinical adoption of exosomes for IRI therapies. Therefore, this review article overviews the administration routes of exosomes from different sources, such as mesenchymal stem cells and other somatic cells, in the context of IRI treatment. Furthermore, this article covers how the delivered exosomes modulate molecular pathways of recipient cells, aiding in the prevention of cell death and the promotions of regeneration in IRI models. In the end, this article discusses the ongoing research efforts and propose future research directions of exosome-based therapies.

Graphical Abstract

more » « less
Author(s) / Creator(s):
; ; ; ; ;
Publisher / Repository:
Springer Science + Business Media
Date Published:
Journal Name:
Nano Convergence
Medium: X
Sponsoring Org:
National Science Foundation
More Like this
  1. Abstract

    Extracellular vesicles (EVs) released by regenerative cells such as mesenchymal stem cells are effective facilitators of healing, therapy, and repair. Conversely, EVs released from infected and/or diseased cells could be useful as markers in the detection and diagnosis of disease conditions such as cancer at their earliest most detectable, and treatable stage. A very important type of EVs, termed exosomes offer a hypothetical new paradigm in disease detection, diagnosis, and treatment. A broad range of exosome‐based biomedical and therapeutic applications are now being evaluated in recent clinical trials. Exosomes are found in virtually all bodily fluids and cells and are capable of crossing tight junctions and toughly regulated boundaries such as the blood–brain barrier. Exosomes' expedition ends when they are taken up by bystander cells which corroborates the fact that they are conduits for cells releasing them. Exosomes released by diseased cells have been associated with cell‐to‐cell progression of diseases like viral disease, neurodegeneration, and certain cancers. Due to high discrimination in most disease conditions, exosome uptake is usually cell‐specific. Lots of research evidence have revealed that infusion of exosomes derived from regenerative cells such as stem cells could impede the development of certain infections and age‐related diseases by activating self‐repair machinery through RNA, DNA, protein, and lipid transfer between cells in patients. They have also been demonstrated in the restoration of the circulating population of exosomes in tissues and the fluid of recipients. The first human clinical trials of exosome therapies are now underway, establishing the future of regenerative exosome in regenerative medicine.

    This article is categorized under:

    Cancer > Stem Cells and Development

    Immune System Diseases > Stem Cells and Development

    Immune System Diseases > Molecular and Cellular Physiology

    more » « less
  2. Abstract

    Stem cell−based therapies for various ailments have attracted significant attention for over a decade. However, low retention of transplanted cells at the damaged site has hindered their potential for use in therapy. Tissue engineered grafts with fibrillar structures mimicking the extracellular matrix (ECM) can be potentially used to increase the retention and engraftment of stem cells at the damaged site. Moreover, these grafts may also provide mechanical stability at the damaged site to enhance function and regeneration. Among all the methods to produce fibrillar structures developed in recent years, electrospinning is a simple and versatile method to produce fibrous structures ranging from a few nanometers to micrometers. Coaxial electrospinning enables production of a mechanically stable core with a cell‐binding sheath for enhanced cell adhesion and proliferation. Furthermore, this process provides an alternative to functionalized engineered scaffolds with specific compositions. The present article describes the protocol for developing a polycaprolactone (PCL) core and gelatin/gelatin methacrylate (GelMA) sheath laden with stem cells for various regenerative engineering applications. © 2021 Wiley Periodicals LLC.

    This article was corrected on 18 July 2022. See the end of the full text for details.

    Basic Protocol 1: Uniaxial PCL electrospinning

    Basic Protocol 2: Coaxial electrospinning

    Support Protocol 1: Scaffold characterization for Basic Protocols 1 and 2

    Basic Protocol 3: Cell seeding on uniaxial and coaxial electrospun scaffolds and MTS assay

    Support Protocol 2: Preparation of scaffold with cells for scanning electron microscopy

    more » « less
  3. Abstract

    As the recognition between natural killer (NK) cells and cancer cells does not require antigen presentation, NK cells are being actively studied for use in adoptive cell therapies in the rapidly evolving armamentarium of cancer immunotherapy. In addition to utilizing NK cells, recent studies have shown that exosomes derived from NK cells also exhibit antitumor properties. Furthermore, these NK cell‐derived exosomes exhibit higher stability, greater modification potentials and less immunogenicity compared to NK cells. Therefore, technologies that allow highly sensitive and specific isolation of NK cells and NK cell‐derived exosomes can enable personalized NK‐mediated cancer therapeutics in the future. Here, a novel microfluidic system to collect patient‐specific NK cells and on‐chip biogenesis of NK‐exosomes is proposed. In a small cohort of non‐small cell lung cancer (NSCLC) patients, both NK cells and circulating tumor cells (CTCs) were isolated, and it is found NSCLC patients have high numbers of NK and NK‐exosomes compared with healthy donors, and these concentrations show a trend of positive and negative correlations with bloodborne CTC numbers, respectively. It is further demonstrated that the NK‐exosomes harvested from NK‐graphene oxide chip exhibit cytotoxic effect on CTCs. This versatile system is expected to be used for patient‐specific NK‐based immunotherapies along with CTCs for potential prognostic/diagnostic applications.

    more » « less
  4. Abstract

    Implantation of stem cells for tissue regeneration faces significant challenges such as immune rejection and teratoma formation. Cell‐free tissue regeneration thus has a potential to avoid these problems. Stem cell derived exosomes do not cause immune rejection or generate malignant tumors. Here, exosomes that can induce osteogenic differentiation of human mesenchymal stem cells (hMSCs) are identified and used to decorate 3D‐printed titanium alloy scaffolds to achieve cell‐free bone regeneration. Specifically, the exosomes secreted by hMSCs osteogenically pre‐differentiated for different times are used to induce the osteogenesis of hMSCs. It is discovered that pre‐differentiation for 10 and 15 days leads to the production of osteogenic exosomes. The purified exosomes are then loaded into the scaffolds. It is found that the cell‐free exosome‐coated scaffolds regenerate bone tissue as efficiently as hMSC‐seeded exosome‐free scaffolds within 12 weeks. RNA‐sequencing suggests that the osteogenic exosomes induce the osteogenic differentiation by using their cargos, including upregulated osteogenic miRNAs (Hsa‐miR‐146a‐5p, Hsa‐miR‐503‐5p, Hsa‐miR‐483‐3p, and Hsa‐miR‐129‐5p) or downregulated anti‐osteogenic miRNAs (Hsa‐miR‐32‐5p, Hsa‐miR‐133a‐3p, and Hsa‐miR‐204‐5p), to activate the PI3K/Akt and MAPK signaling pathways. Consequently, identification of osteogenic exosomes secreted by pre‐differentiated stem cells and the use of them to replace stem cells represent a novel cell‐free bone regeneration strategy.

    more » « less
  5. Abstract

    Science and medicine have become increasingly “human‐centric” over the years. A growing shift away from the use of animals in basic research has led to the development of sophisticated in vitro models of various tissues utilizing human‐derived cells to study physiology and disease. The human cornea has likewise been modeled in vitro using primary cells derived from corneas obtained from cadavers or post‐transplantation. By utilizing a cell's intrinsic ability to maintain its tissue phenotype in a pre‐designed microenvironment containing the required growth factors, physiological temperature, and humidity, tissue‐engineered corneas can be grown and maintained in culture for relatively long periods of time on the scale of weeks to months. Due to its transparency and avascularity, the cornea is an optimal tissue for studies of extracellular matrix and cell‐cell interactions, toxicology and permeability of drugs, and underlying mechanisms of scarring and tissue regeneration. This paper describes methods for the cultivation of corneal keratocytes, fibroblasts, epithelial, and endothelial cells for in vitro applications. We also provide detailed, step‐by‐step protocols for assembling and culturing 3D constructs of the corneal stroma, epithelial‐ and endothelial‐stromal co‐cultures and isolation of extracellular vesicles. © 2020 Wiley Periodicals LLC.

    Basic Protocol 1: Isolating and culturing human corneal keratocytes and fibroblasts

    Basic Protocol 2: Isolating and culturing human corneal epithelial cells

    Basic Protocol 3: Isolating and culturing human corneal endothelial cells

    Basic Protocol 4: 3D corneal stromal construct assembly

    Basic Protocol 5: 3D corneal epithelial‐stromal construct assembly

    Basic Protocol 6: 3D corneal endothelial‐stromal construct assembly

    Basic Protocol 7: Isolating extracellular vesicles from corneal cell conditioned medium

    Support Protocol: Cryopreserving human corneal fibroblasts, corneal epithelial cells, and corneal endothelial cells

    more » « less